B40.81 Blastomycotic meningoencephalitis

Name of the Condition

• Blastomycotic meningoencephalitis

Summary

Blastomycotic meningoencephalitis is a severe fungal infection of the central nervous system (CNS) caused by Blastomyces dermatitidis (and related species). It occurs when the fungus disseminates from a primary site (typically the lungs) to the meninges and brain, leading to inflammation and neurological impairment. The condition is rare but serious, often presenting with acute or subacute symptoms and requiring prompt diagnosis and treatment to prevent complications.

Causes

The infection results from hematogenous spread of Blastomyces yeast from a primary pulmonary or cutaneous site to the CNS. Inhalation of airborne spores from soil or decaying organic matter in endemic regions is the initial route of exposure. Once in the lungs, spores convert to yeast, multiply, and may enter the bloodstream, crossing the blood-brain barrier to infect the meninges and brain parenchyma. Direct CNS inoculation is extremely rare.

Risk Factors

• Residence in or travel to endemic areas (e.g., parts of North America, particularly the Ohio and Mississippi River valleys).
• Immunocompromised states (e.g., HIV/AIDS, organ transplantation, chronic steroid use).
• Advanced age.
• Untreated or disseminated blastomycosis at other sites.

Symptoms

• Headache (often severe and persistent).
• Fever, neck stiffness, or photophobia (meningeal irritation).
• Altered mental status, confusion, or lethargy.
• Seizures or focal neurological deficits (e.g., weakness, vision changes).
• Nausea, vomiting, or photophobia.
• Symptoms of concurrent disseminated disease (e.g., pulmonary or skin lesions).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory testing. Lumbar puncture with cerebrospinal fluid (CSF) analysis may show elevated protein, low glucose, and pleocytosis (often lymphocytic). CSF or tissue cultures (e.g., from biopsy) confirm Blastomyces growth. Imaging (MRI/CT) of the brain may reveal meningeal enhancement, abscesses, or edema. Serologic tests (e.g., antigen detection) or PCR may support diagnosis, though culture remains definitive.

Treatment Options

Treatment requires systemic antifungal therapy, typically with amphotericin B (initially) followed by an azole (e.g., itraconazole) for maintenance. Duration depends on severity and immune status, often lasting 6–12 months or longer. Adjunctive therapies (e.g., corticosteroids for cerebral edema) may be used. Surgical intervention is rare but may be needed for abscess drainage or shunt placement.

Prognosis and Follow-Up

Prognosis depends on early diagnosis, immune status, and treatment adherence. Immunocompetent patients often recover with therapy, but immunocompromised individuals face higher risks of relapse or mortality. Follow-up includes monitoring for symptom resolution, repeat imaging (if needed), and CSF testing to confirm clearance. Long-term neurological sequelae (e.g., cognitive impairment) may occur.

Complications

• Permanent neurological damage (e.g., cognitive deficits, motor impairment).
• Hydrocephalus or increased intracranial pressure.
• Seizure disorders.
• Recurrent infection (especially in immunocompromised patients).
• Multi-organ failure in severe cases.

Lifestyle & Prevention

• Avoid exposure to soil or decaying matter in endemic areas (e.g., wear masks during excavation).
• Promptly treat primary blastomycosis to prevent dissemination.
• Maintain immune health (e.g., manage HIV, avoid unnecessary immunosuppressants).
• Seek care for persistent respiratory or systemic symptoms in endemic regions.

When to Seek Professional Help

Seek immediate medical attention for severe headache, fever, neck stiffness, confusion, or neurological changes (e.g., weakness, seizures), especially if residing in or traveling to endemic areas. Early evaluation is critical to prevent irreversible CNS damage.

Tips for Medical Coders

Code B40.81 is specific to blastomycotic meningoencephalitis. Document the presence of CNS involvement (e.g., meningeal or brain tissue infection) and confirm the fungal etiology. Ensure clinical correlation with symptoms, imaging, or laboratory results (e.g., CSF analysis, culture) to support the diagnosis. Differentiate from other CNS infections (e.g., bacterial meningitis) to avoid miscoding.